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DownlInflammatory mediators present in the tumor milieu may promote cancer progression and are consid-
ered promising targets of novel biological therapies. We previously reported that the marine antitumor
agent trabectedin, approved in Europe in 2007 for soft tissue sarcomas and in 2009 for ovarian cancer,
was able to downmodulate the production of selected cytokines/chemokines in immune cells. Patients with
myxoid liposarcoma (MLS), a subtype characterized by the expression of the oncogenic transcript FUS-
CHOP, are highly responsive to trabectedin. The drug had marked antiproliferative effects on MLS cell lines
at low nanomolar concentrations. We tested the hypothesis that trabectedin could also affect the inflam-
matory mediators produced by cancer cells. Here, we show that MLS express several cytokines, chemo-
kines, and growth factors (CCL2, CCL3, CCL5, CXCL8, CXCL12, MIF, VEGF, SPARC) and the
inflammatory and matrix-binder protein pentraxin 3 (PTX3), which build up a prominent inflammatory
environment. In vitro treatment with noncytotoxic concentrations of trabectedin selectively inhibited the
production of CCL2, CXCL8, IL-6, VEGF, and PTX3 by MLS primary tumor cultures and/or cell lines. A
xenograft mouse model of human MLS showed marked reduction of CCL2, CXCL8, CD68+ infiltrating
macrophages, CD31+ tumor vessels, and partial decrease of PTX3 after trabectedin treatment. Similar find-
ings were observed in a patient tumor sample excised after several cycles of therapy, indicating that the
results observed in vitro might have in vivo relevance. In conclusion, trabectedin has dual effects in lipo-
sarcoma: in addition to direct growth inhibition, it affects the tumor microenvironment by reducing the
production of key inflammatory mediators. Cancer Res; 70(6); 2235–44. ©2010 AACR.Introduction
Trabectedin (ET-743; Yondelis) is the first marine-derived
anticancer drug that has reached the market. It was ap-
proved in Europe in 2007 for second line treatment of soft
tissue sarcomas and in 2009 for relapsed ovarian cancer in
combination with pegylated liposomal doxorubicin. Studies
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on June 3, 202cancerres.aacrjournals.org oaded from diseases, including breast and prostate cancer, as suggested
by the early clinical trials. Originally derived from the ma-
rine tunicate Ecteinascidia turbinata, it is now obtained by
a semisynthetic method starting from cyanosaframycin B,
an antibiotic that can be produced in large quantities by
fermentation of Pseudomonas fluorescens (1). Trabectedin is
a DNA-binding agent interfering with gene transcription,
regulation, and DNA repair machinery (2, 3), and is able
to induce cell cycle perturbation with a delayed S phase
progression and accumulation of cells in G2 phase (4). Its
mechanism of action is incompletely understood and pre-
sents some unique features. Unlike most conventional anti-
tumor agents, it binds the minor groove of DNA at the N2
position of guanines, bending the DNA sharply towards the
major groove (3, 5, 6); its cytotoxicity seems to be depen-
dent on the efficiency of transcription-coupled nucleotide
excision repair, a deficiency of which makes cells less sen-
sitive to the drug; instead, cells carrying defects of homol-
ogous recombination repair, e.g., for BRCA gene mutations,
are especially sensitive (7–9).
A distinct histologic subtype of soft tissue sarcoma is the
myxoid liposarcoma (MLS) which is particularly susceptible
to trabectedin (10–12). Second line treatment in patients
with MLS was reported to be exceptionally effective with2235
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logic complete responses (10). Most MLS carry the fusion
gene FUS-CHOP, caused by the t(12:16) chromosome translo-
cation, considered the pathogenetic lesion of this tumor (13–
15). FUS encodes an RNA and DNA binding protein. CHOP is
a stress-induced transcription factor forming DNA binding
dimers with CAAT/enhancer binding proteins, acting as a
negative regulator. Members of the CAAT/enhancer binding
protein family have major roles in adipogenesis and their
function can be subverted by FUS-CHOP, with a consequent
block in adipogenesis differentiation. The oncogenic poten-
tial of the transcript has been proven in FUS-CHOP transgen-
ic animals which develop liposarcoma and in transformed
mesenchymal progenitors (16, 17). The high susceptibility
of MLS raised the question of whether FUS-CHOP is a target
of trabectedin. A study conducted on MLS cells showed
that trabectedin does not affect the transcription of the
FUS-CHOP chimera, but blocks its transactivating ability by
inducing the detachment of FUS-CHOP protein from the pro-
moters of target genes (18).
In patients with MLS undergoing trabectedin therapy, it is
not infrequent to observe clinical responses after several cy-
cles of chemotherapy, unlike what happens with most cyto-
toxic drugs. In addition, radioimaging (magnetic resonance
imaging and computed tomography scans) show that clinical
responses are associated with a decrease in tumor density
that precedes tumor shrinkage (10, 19). It is therefore sus-
pected that trabectedin plays biological effects on the tumor
microenvironment other than direct cytotoxicity to cancer
cells.
On the basis of our previous findings that trabectedin
reduces the production of some cytokines/chemokines in
immune cells (20), we postulated the hypothesis that a re-
duction of inflammatory mediators at the tumor site might
contribute to its antitumor efficacy. It is now established
that a persistent cancer-related inflammation promotes tu-
mor cell proliferation, survival, and spread (21–23). Genetic
events causing neoplasia actively support the construction
of an inflammatory milieu. Examples of oncogene-driven
activation of the inflammatory cascade include the onco-
gene RET in thyroid papillary carcinoma, and RAS, BRAF,
or mutated tumor suppressor genes in different tumors
(22, 24, 25). Little is known about the downstream target
genes activated by the oncogenic transcript FUS-CHOP,
particularly inflammatory genes, with the exception of IL-6,
and recently, IL-8 (26, 27).
In this work, we investigated the spectrum of inflamma-
tory mediators present in the microenvironment of MLS
and the effect of trabectedin treatment in vitro and in vivo.
We show that MLS cancer cells build up a prominent in-
flammatory microenvironment. Trabectedin significantly re-
duced the expression and production of CCL2, CXCL8, IL-6,
VEGF, and the proinflammatory protein and matrix binder
pentraxin 3 (PTX3). Mice transplanted with human MLS
showed lower infiltration of CD68 macrophages and lower
numbers of vessels after therapy. This anti-inflammatory ef-
fect of trabectedin might contribute to its antitumor effica-
cy in MLS.Cancer Res; 70(6) March 15, 2010
on June 3, 202cancerres.aacrjournals.org Downloaded from Materials and Methods
Drug. Trabectedin (PharmaMar, Spain) was dissolved in
DMSO to 1 mmol/L, and kept at −20°C.
MLS cell lines. MLS cell lines, 402.91 and 1765, the fibro-
sarcoma cell line HT1080 and its subline transfected with
FUS-CHOP, were kindly provided by Dr. Pierre Aman (Uni-
versity of Gothenburg, Sweden). Cells were grown in RPMI
1640 with 10% FCS (Lonza), Ultraglutamine 1 200 mmol/L
(Lonza), and Pen/Strep. The liposarcoma cell line SW872,
lacking FUS-CHOP (kindly provided by Prof. Bussolati, Uni-
versity of Parma, Parma, Italy), was grown in complete
DMEM + 10% FCS. Tumor cell lines were routinely verified
by morphology, growth curve analysis, and tested for Myco-
plasma. Primary cultures of human MLS were obtained
from surgical specimens. Tumors were minced and enzy-
matically digested with 500 units/mL of collagenase II
and 2 units/mL of DNase for 1 h at 37°C. Cell suspension
was filtered and the cells were seeded in ISCOV-1 medium
+ 10% FCS, L-glutamine 200 mmol/L, and Pen/Strep.
Establishment of MLS xenografts. Fragments of human
MLS tumor biopsies were established as xenografts
through serial transplantation in nude mice for a limited
number of passages. The presence of fusion transcript type
corresponding to the original tumors was assessed by fluo-
rescence in situ hybridization analysis at each passage. Mice
were treated with trabectedin (0.15 mg/kg, q7dx3) starting
when tumors were palpable. Tumors for immunohisto-
chemistry (n = 3) were excised 48 h after the third dose.
Five to seven sections were analyzed from each tumor.
Cell cycle analysis, growth inhibition, cytotoxic effect,
and apoptosis. Exponentially growing cells were treated
for 1 h, or as specified, with different concentrations of
trabectedin, then washed with PBS and fresh drug-free me-
dium was added. The growth-inhibitory effect of trabecte-
din was evaluated at different times after drug washout.
The effect of trabectedin on clonogenicity was evaluated
as previously described (28). Cell cycle analysis was per-
formed by flow cytometry on cells fixed in 70% cold eth-
anol and kept at 4°C before DNA staining. To detect
bromodeoxyuridine (BrdUrd) incorporated into DNA, fixed
cells were incubated with anti-BrdUrd monoclonal anti-
body (Becton Dickinson) and DNA detected by propidium
iodide (4). To analyze apoptotic death after trabectedin
treatment, mRNA levels were tested with TaqMan Human
Apoptosis Array (Applied Biosystems), following the
instructions of the manufacturer.
Measurement of inflammatory mediators. Tumor cell
lines were starved (without FCS) for 18 h and treated with
different doses of trabectedin for 4 h. Cells were washed
and stimulated or not with tumor necrosis factor α (TNFα;
20 ng/mL). Total RNA extraction was done with Trizol. cDNA
was synthesized by random priming from 1 μg of total RNA
with GeneAmp RNA PCR kit (Applied Biosystems). mRNA le-
vels of 91 genes related to inflammation were tested with
custom TaqMan Human Inflammation Array (Applied Bio-
systems). Real-time PCR was performed using SYBR Green
dye. Sequences of specific primer pairs (Invitrogen) wereCancer Research
0. © 2010 American Association for Cancer Research. 
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Rev, CACAGATCTCCTTGGCCACAA; hCXCL8—For, CCAG-
GAAGAAACCACCGGA; Rev, GAAATCAGGAAGGCTGC-
CAAG; hPTX3—For, CGAAATAGACAATGGACTCCATCC;
Rev, CAGGCGCACGGCGT; h-Actin—For, TCACCCA-
CACTGTGCCCATCTACGA; Rev, CAGCGGAACCGCT-
CATTGCCAATGG.
For each gene, mRNA was normalized to β-actin mRNA
(ΔCt). Results are shown as arbitrary units (2−ΔCt × 10,000).
Fold change (2−ΔΔCt) of trabectedin-treated cells is calculat-
ed compared with the untreated cells.
Protein levels were measured by ELISA in cell superna-
tants collected at 24 h culture after drug treatment (4 h)
and washout. Under these conditions, cell viability was
checked and was usually >87% for all drug concentrations
shown. IL-1β, IL-6, IL-10, CCL2, CXCL8, TNFα, and VEGF
were determined by the BioPlex Protein Array Luminex 100www.aacrjournals.org
on June 3, 202cancerres.aacrjournals.org Downloaded from System (Bio-Rad). Data acquisition and analysis were done
using BioPlex Manager software. PTX3 detection was mea-
sured by ELISA as previously described (29).
Immunohistochemistry. Antibodies used for immunohis-
tochemistry of surgical MLS specimens were antihuman
CD31 (clone JC70A; Dako), antimouse CD31 (clone MEC13.3;
PharMingen), antimurine CD68 (clone FA-11; HyCult Biotech-
nology), antihuman CD68 (clone KP1; Dako), antihuman CCL2
(clone 5D3-F7; Alexis Biochemicals), antihuman CXCL8 (clone
6217; R&D Systems), antihuman PTX3 (polyclonal), and anti-
murine PTX3 (clone MNB1; Alexis Biochemicals).
Patients with MLS. Eighteen patients were admitted at
the National Cancer Institute (Milan Italy) with persistent
disease after standard chemotherapy and were eligible to tra-
bectedin. In all patients, the diagnosis of MLS was confirmed
by histology and cytogenetic analyses (presence of FUS-
CHOP transcript). Blood samples were collected immediatelyFigure 1. Cell cycle perturbation and growth inhibition in MLS cells. A, cells were treated with trabectedin for 1 h at the indicated concentrations,
washed, and cultured at different time points before testing. Top right, inhibition of proliferation of 402.91 cells in clonogenic assays tested at 15 d.
Points, mean of three experiments (five replicates); bars, SD. Left, cell cycle perturbation induced by trabectedin (1 h) in 402.91 cells and performed at
different time intervals after drug washout. Bottom right, cell counts over 72 h. B, biparametric BrdUrd/DNA flow cytometric analysis performed in control
cells (I) at 0 h, after 24 h (II), and finally, post–trabectedin washout (III). The DNA histograms of the whole population (Full DNA), BrdUrd-negative
(G1 and G2-M), and BrdUrd-positive (S) are shown. C, left, cell cycle perturbation induced by 24 h of trabectedin exposure on a primary MLS culture at
different time intervals after drug washout (24 h T, treatment for 24 h; 24–48–72 h R, times of recovery after drug washout). Right, cell counts over 72 h.
D, upregulation of mRNA levels of apoptotic genes at three different time points after drug treatment (5 nmol/L).Cancer Res; 70(6) March 15, 2010 2237
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(B) Effect of trabectedin on TNF-stimulated cells (fold change)
Gene 402.91 1765 HT1080 HT1080 FUS-CHOP
CCL2 0.25 0.21 0.08 0.06
CCL5 0.69 0.32 0.17 0.18
CXCL8 0.81 0.40 0.35 0.53
TNF 4.3 2.1 0.8 0.6
TNFRS1A 0.9 1.1 0.8 1.2
TNFRSF1B 1.6 1.0 0.2 1.0
IL-1β 0.81 0.35 0.39 0.36
IL-6 3.31 1.44 0.02 0.75
M-CSF 1.33 0.90 0.97 1.52
MIF 1.44 1.60 1.01 1.39
PTX3 0.50 0.45 0.66 0.54
SPARC 1.08 1.35 0.95 1.60
TGFβ 1.28 1.48 1.0 1.0
NOTE: A, total RNAwas extracted fromTNFα-stimulated 402.91 and 1765MLScell lines, fibrosarcomaHT1080 cell line and its variant
FUS-CHOP–transfected, and from surgical samples from two patients withMLS (tumor 1 and tumor 2). Results are shown as arbitrary
units (2−ΔCt × 10,000) that correlate with transcriptional activity of genes. B, cell lines treated with trabectedin (5 nmol/L). Results are
expressed as fold change (2−ΔΔCt) of trabectedin-treated cells compared with untreated. Und.: undetermined (i.e. > 35 cycles).
Germano et al.
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PTX3 levels were measured by ELISA.
Statistical analysis. Prism software (GraphPad) and Mi-
crosoft Excel were used for all statistical analyses. Student's
t tests were used to determine statistically significant differ-
ences between experimental groups.
Results
Trabectedin induces cell cycle perturbation in MLS
cells and triggers cell death. We first investigated the directCancer Res; 70(6) March 15, 2010
on June 3, 202cancerres.aacrjournals.org Downloaded from effects of trabectedin on human MLS. A short 1-hour expo-
sure affected the proliferation of the cell line 402.91. Figure
1A (top right) shows the results of a representative clono-
genic experiment: a strong dose-dependent effect was ob-
served with 50% reduction at concentration of 1.5 nmol/L.
Cell cycle analysis, performed at different time intervals after
drug treatment, showed that trabectedin induced a block of
cell proliferation and a dose-dependent accumulation of cells
in S phase (5 and 10 nmol/L), followed by a G2-M block
(Fig. 1A, left). A strong growth inhibition consequent to G2-
M block is depicted in Fig. 1A (bottom right). BiparametricTable 1. TaqMan human inflammation array(A) mRNA levels of inflammation-related genes in tumor cell lines and surgical tumor samplesGene 402.91 1765 HT10800.HT1080 FUS-CHOP © 2010 American AssociatiTumor 1Cancer
on for Cancer ReTumor 2CCL2 3,329 590 23 178 316 116
CCL3 Und. Und. 1.2 1.0 2,879 222
CCL5 314 87 44 497 956 174
CXCL8 4,352 3,815 1,975 5,946 1,147 23
CXCL12 Und. 1.82 Und. Und. 60,965 32,087
CXCR4 0.2 1.4 Und. Und. 236 76
TNF 4.5 2.7 4.8 12 51 5.8
TNFRS1A 72 41 187 439 9,037 1,508
TNFRS1B 11 3.3 1.6 46 649 103
IL-1β 73 129 656 55 415 68
IL-6 64 58 85 2.6 Und. Und.
M-CSF 175 88 314 254 1,382 529
MIF 592 451 2,891 6,417 51,408 15,104
PTX3 3,171 717 728 3,438 63,863 7,051
SPARC 2,717 960 1,036 1,582 112,667 19,738
TGFβ 20 34 321 1,349 4,027 613
VEGF 17 13.4 93 192 8,173 1,088
ANGPT1 Und. Und. 0.6 0.5 19,801 3,820Research
search. 
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Published OnlineFirst March 9, 2010; DOI: 10.1158/0008-5472.CAN-09-2335 flow cytometric BrdUrd/DNA analysis showed that at 24
hours after drug treatment (1 hour) and washout, both
BrdUrd-positive (i.e., cells in S phase during drug treatment)
as well as BrdUrd-negative (i.e., cells in G1 or G2-M phase
during drug treatment) accumulated in G2-M phases
(Fig. 1B). Similar results were observed with primary cultures
obtained from a MLS surgical specimen (Fig. 1C). Prolonged
drug exposure to trabectedin induced a cytotoxic effect in
402.91 and 1765 cell lines; after 48 hours of continuous expo-
sure to 2.5 nmol/L, cell death was 70% and 50%, respectively.
At 24 hours, it was <20% at 5 nmol/L (data not shown). The
majority of cells were in necrosis but a proportion of Annex-
in V+ PI− cells (22%) was also detected; as shown in Fig. 1D
(bottom), some apoptosis genes were upregulated at 18 hours:
BIK, FAS, TRAILR1 (DR4), and caspase 10. Overall, the results
show that MLS cells are highly susceptible to trabectedin
within the low nanomolar range.
MLS cells express inflammatory mediators and build up
an inflammatory microenvironment. As little is known
about the presence of an inflammatory microenvironment in
human MLS, we first explored a wide panel of biological med-
iators with a customized TaqMan Inflammation Array. mRNA
was obtained from (a) frozen sections of two distinct human
MLS surgical samples; (b) the MLS cell lines 402.91 and 1765;www.aacrjournals.org
on June 3, 202cancerres.aacrjournals.org Downloaded from (c) the fibrosarcoma cell line HT1080 and its FUS-CHOP–
transduced variant. Table 1 shows that several inflammatory
mediators were highly expressed in the tumor milieu of the
two surgical MLS samples. For instance, chemokines (CCL2,
CCL3, CCL5, CXCL8,CXCL12, CXCR4), cytokines and growth
factors (TNF and receptors, IL-1β, M-CSF, MIF, TGFβ,VEGF,
and angiopoietin 1), and matrix-binding proteins (PTX3 and
SPARC). PTX3, originally described by our group, is an inflam-
matory protein acting as a soluble pattern recognition recep-
tor and is also involved in the organization of the extracellular
matrix (ECM; refs. 29, 30). In addition, molecules related to in-
filtrating myeloid cells (CD68, CD14, M-CSFR; Supplementary
Fig. S1) were highly expressed. Some inflammatory mediators
were also elevated in the cell lines 402.91 and 1765: CCL2,
CCL5, CXCL8, PTX3, SPARC, M-CSF, and MIF. The FUS-
CHOP–transfected HT1080 cell line was tested to investigate
the inflammation-related genes activated downstream of the
oncogenic transcript distinctive of MLS. HT1080-FUS-CHOP
cells expressed higher levels of CCL2, CCL5, CXCL8, MIF,
PTX3, TGFβ, and VEGF compared with HT1080 cells, indicat-
ing that the transactivating ability of FUS-CHOP indeed in-
volves genes of the inflammatory response.
Selected factors were confirmed by immunohistochemistry
in surgical tumor specimens as well as in MLS xenograftsFigure 2. Immunohistochemistry of CD31, CD68, CCL2, CXCL8, and PTX3 in tumor tissues from (A) patient MLS surgical specimens and (B) MLS
xenografts established in nude mice (m, antimurine antibodies; h, antihuman antibodies). Original magnifications: anti-CD31, antimouse CD68,
and anti-PTX3 (×10); antihuman CD68, anti-CXCL8, and anti-CCL2 (×20); insets (×100).Cancer Res; 70(6) March 15, 2010 2239
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ic analysis of xenografted MLS confirmed that growing tu-
mors retained the original fusion transcript type (data not
shown). Staining for CXCL8, CCL2, PTX3, and for macrophage
infiltration (CD68) and vessels (CD31) are shown in Fig. 2.
Both samples from patient tumors (A) and xenograft tumors
(B) have a florid angiogenesis, a remarkable macrophage con-
tent, and tumor cells producing CXCL8 and CCL2. The whole
sections stained strongly for PTX3, which was secreted by
cancer cells (insets). To further control PTX3 origin in xeno-
graft tumors, an antimurine PTX3 was used. Supplementary
Fig. S2 shows that tumor cells were negative, only few scat-
tered stromal cells were positive.
Overall, the results highlight that human MLS build up a
prominent inflammatory microenvironment. We next deter-
mined the effect of trabectedin on this inflammatory network.
Trabectedin inhibits the production of selected inflam-
matory mediators in vitro. In vitro treatment of the two
cell lines (402.91 and 1765) with trabectedin reduced
mRNA levels of selected mediators: CCL5, CXCL8, IL1β in
1765 cells, and CCL2 and PTX3 in both cell lines (Table 1).
Other expressed genes (TGFβ, TNFRII, M-CSF, MIF, and
SPARC) were unaffected, ruling out the occurrence of a non-
specific cytotoxic effect. In HT1080-FUS-CHOP cells, trabec-
tedin strongly reduced the expression of CCL2, CXCL8, as
well as PTX3 (Table 1). Selected mediators were corroborat-
ed by real-time PCR in untreated and TNF-stimulatedCancer Res; 70(6) March 15, 2010
on June 3, 202cancerres.aacrjournals.org Downloaded from 402.91 and 1765 cells. Inhibition of CCL2, CXCL8, and
PTX3 was confirmed after trabectedin treatment (Supple-
mentary Fig. S3)
Determination of protein levels was performed by ELISA in
cell supernatants. In the absence of exogenous stimuli, con-
siderable levels of CCL2, CXCL8, and especially of PTX3, were
secreted by both cell lines. Lower levels of TNFα, IL-1β, IL-6,
IL-10, and VEGF were also detected (Supplementary Fig. S4).
To assess the inhibitory effect of trabectedin, cell superna-
tants were collected after 24 hours of drug treatment
(4 hours) and washout. Under these conditions, cell viability
was usually >87% for all drug concentrations shown. Both
constitutive and TNF-induced production of all three in-
flammatory mediators was dose-dependently reduced,
with a more dramatic effect in TNF-induced production.
Figure 3A shows representative experiments. Mean inhibition
of CCL2 was 61.2% and 64.6% at 2.5 nmol/L of trabectedin
for 402.91 (n = 8 experiments) and 1765 (n = 6), respec-
tively; at 5 nmol/L, a complete block of CCL2 production
was observed (>88% for both cell lines). CXCL8 levels were al-
so reduced with 64.9% and 38.8% inhibition at 5 nmol/L
(402.91 and 1765, respectively; n = 4). For PTX3, reduction
was higher in 402.91 cells (60.5% at 2.5 nmol/L and 79.6% at
5 nmol/L) compared with 1765 cells (39.6% at 2.5 nmol/L and
50% at 5 nmol/L; n = 6). Cell-associated PTX3 was tested by
Western blot in 402.91 cells and was also downmodulated by
50% (Supplementary Fig. S5).Figure 3. Trabectedin inhibits the production of inflammatory mediators in MLS cells. A, CCL2, PTX3, and CXCL8 protein levels in 402.91 and 1765 cells
measured by ELISA. Cells were treated for 4 h with trabectedin, washed and incubated with or without 20 ng/mL of TNFα for 24 h. Results are from a
representative experiment (four to eight experiments performed). B, CCL2, CXCL8, IL-6, VEGF, and PTX3 protein levels in primary MLS cultures measured
by ELISA. Cells were treated for 4 h with trabectedin, washed and incubated for 24 h. Results are from four different primary MLS cultures (five
cultures for PTX3). Trabectedin: 5 nmol/L (black columns), 10 nmol/L (gray column). *, P < 0.05; **, P < 0.01 (Student's t test).Cancer Research
0. © 2010 American Association for Cancer Research. 
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duction by primary tumor cultures derived from surgical
MLS samples. As observed with the cell lines, primary MLS
cultures constitutively produced CCL2, CXCL8, IL-6, VEGF,
and high levels of PTX3 (Supplementary Fig. S4). Figure 3B
shows that CCL2 and CXCL8 were reduced by trabectedin
with variable levels of inhibition. The mean decrease of
CCL2 was 50.82% (range, 29.4–64.8%), whereas CXCL8 de-
creased by 48.7% (range, 38.4–68.2%). IL-6 and VEGF were
also significantly downmodulated, the mean inhibition of
IL-6 was 52% (range, 38.8–72.4%), whereas VEGF was at
40.2% (range, 23.1–50.5%) in three out of four cultures.
PTX3 was also reduced, with a mean inhibition of 44.1%
(range, 13.3–70%). Culture no. 3 secreted very high levels of
PTX3 and a decrease was evident only at 10 nmol/L.
Of interest, in parallel experiments, we noticed that PTX3
levels (mRNA and protein) were not decreased in lipopoly-
saccharide-stimulated monocytes. We therefore tested other
PTX3-producing cells. TNF-stimulated human umbilical vas-
cular endothelial cell and a liposarcoma cell line (SW872) not
harboring the FUS-CHOP transcript were not inhibited in
their PTX3 production (Supplementary Fig. S6), indicating
that trabectedin inhibits PTX3 only in FUS-CHOP–positive
cells. Overall, a brief exposure to trabectedin significantly re-
duced the production of key inflammatory mediators by MLS
cell lines and primary cultures.
Trabectedin reduces the inflammatory microenviron-
ment in vivo. To investigate whether a reduction of inflam-www.aacrjournals.org
on June 3, 202cancerres.aacrjournals.org Downloaded from matory mediators also occurs in vivo, mice bearing xenograft
tumors were treated with three doses of i.v. trabectedin; tu-
mor samples were excised 48 hours after the third dose and
stained for CXCL8, CCL2, PTX3, macrophage infiltration, and
vessels. Pictures from untreated (Fig. 4A) and trabectedin-
treated animals (Fig. 4B) are shown. The number of CD68+
infiltrating macrophages significantly decreased after trabec-
tedin from 72.4 ±8 (mean ± SD, three tumors) to 30.2 ± 6
(n = 3; P < 0.05). Tumor vessels were also strongly reduced,
from 40.5 ± 7(n = 3) to 10.2 ± 5 (n = 3; P < 0.05) in un-
treated and treated animals, respectively. A clear inhibition
of CXCL8 and CCL2 staining and a partial reduction of
PTX3 were observed after treatment.
We had the opportunity to test surgical MLS patient sam-
ples resected after several cycles of trabectedin therapy, from
whom the original bioptic tissue was available. Figure 5A
shows tissues from a patient with clinical response to trabec-
tedin. The surgical sample excised after therapy had a
marked decrease in CD31+ vessels and CD68+ macrophages;
PTX3 positivity was also strongly decreased compared with
the sample before therapy (Fig. 5A). These findings indi-
cate that the reduction of inflammatory mediators observed
in vitro with trabectedin may have in vivo relevance.
Our group tested the potential diagnostic and prognostic
value of plasma PTX3 levels in different pathologies, includ-
ing infectious, cardiovascular, and autoimmune diseases (29,
30). As MLS cancer cells are potent producers of PTX3, it was
of interest to investigate the circulating levels of PTX3 inFigure 4. Immunohistochemistry of antimurine CD31 and CD68 and antihuman CCL2, CXCL8 and PTX3 in MLS xenografts before (A) and after (B)
trabectedin treatment in vivo. Original magnifications: anti-CD31, anti-CD68, and anti-PTX3 (×10); anti-CXCL8 and anti-CCL2 (×20).Cancer Res; 70(6) March 15, 2010 2241
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Published OnlineFirst March 9, 2010; DOI: 10.1158/0008-5472.CAN-09-2335 these patients. Figure 5B shows that median plasma levels of
PTX3 were significantly higher (11,540 pg/mL) compared
with those of healthy donors (2,000 pg/mL) or of cancer pa-
tients with other malignancies (colorectal and liver cancer).
Of 11 patients undergoing therapy with trabectedin, it was
possible to follow the plasma levels of PTX3 in seven cases.
A decrease of circulating PTX3 was observed in four patients
experiencing a measurable clinical response according to the
Response Evaluation Criteria in Solid Tumors (ref. 10; Fig. 5C).
In three other patients (two with low levels of plasma
PTX3), no modification was observed in spite of one partial
response, one stable disease, and a mixed response. Thus,
plasma PTX3 levels in patients with MLS are considerably
elevated; the significance of high PTX3 levels and its validity
as a biomarker of response to therapy in these patients
needs to be further investigated.
Discussion
In this study, we have evaluated multiple effects of trabec-
tedin on MLS cell lines, primary tumor cultures, and MLS xe-
nografts as a direct antiproliferative effect and for the
reduction of selected proinflammatory mediators. In MLS
cells, this compound induces a marked growth inhibitionCancer Res; 70(6) March 15, 2010
on June 3, 202cancerres.aacrjournals.org Downloaded from due to a delay in S phase and a G2-M block and, in a fraction
of cells, subsequent activation of apoptosis. Inhibition of pro-
liferation in vitro was observed at very low concentrations (1–
3 nmol/L) and short exposure times (1 hour), that are realis-
tically achievable according to pharmacokinetic data (19). In-
deed, trabectedin showed high efficacy in advanced MLS (10).
This liposarcoma subtype is characterized by the presence of
the oncogenic fusion transcript FUS-CHOP (16, 17). Whether
FUS-CHOP is a target of trabectedin is an open issue. Several
tumor types which do not express FUS-CHOP are susceptible
to the drug (e.g., other sarcomas, breast and ovarian carcino-
ma). Recent studies indicate that trabectedin has no effect on
the transcription of FUS-CHOP gene, but blocks its transacti-
vating ability causing the detachment of the FUS-CHOP pro-
tein from the promoter of target genes (18).
The mechanism of action of this compound is not lim-
ited to binding and damage of DNA but also includes the
transcriptional inhibition of selected genes (2). We previ-
ously showed that trabectedin reduces the production of
CCL2 and IL-6 in activated macrophages (20). These and
other mediators of the inflammatory response are fre-
quently expressed in the tumor microenvironment by infil-
trating leukocytes, stromal and cancer cells themselves
(21–23). It is generally considered that the presence of aFigure 5. A, immunohistochemistry of CD31, CD68,
and PTX3 in the bioptic sample of MLS tissue performed
before therapy (top) and on the surgical sample obtained
after trabectedin therapy (bottom). B, PTX3 plasma
levels in patients with MLS and in patients with colorectal
and liver cancer. C, PTX3 plasma levels in patients with
MLS receiving trabectedin therapy. PTX3 measurement
was performed before therapy (white columns) and at
the indicated cell cycles (gray columns). SD, stable
disease; PR, partial response; MR, mixed response;
TR, tissue response (decreased tissue density);
PD, progressive disease.Cancer Research
0. © 2010 American Association for Cancer Research. 
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Published OnlineFirst March 9, 2010; DOI: 10.1158/0008-5472.CAN-09-2335 smoldering inflammation in neoplastic tissues promotes
tumor cell survival and proliferation, as well as the main-
tenance of a reactive stroma with neoangiogenesis and
matrix turnover (21–23). Here, we show that MLS cells
produce in vitro and in vivo several cytokines, chemokines,
and growth factors, and that the oncogenic transcript FUS-
CHOP is involved in the activation of the inflammatory
cascade. Trabectedin significantly reduced CCL2, CXCL8,
as well as IL-6 and VEGF in MLS cells and xenografts. Re-
duction of these key inflammatory mediators may repre-
sent an important mechanism of its antitumor efficacy.
CCL2 is a major chemokine promoting monocyte
recruitment at sites of inflammation and tumors, and its ex-
pression significantly correlates with macrophage accumula-
tion (31, 32). In most studies, CCL2-mediated attraction of
macrophages is associated with the angiogenic switch and
poor prognosis (22, 33–36). The chemokine CXCL8 is a potent
mediator of angiogenesis enhancing endothelial cell prolifer-
ation, chemotaxis, survival, and protease activation (32, 37).
Moreover, CXCL8 is directly mitogenic for some cancer cells
and plays a critical role in tumor growth at metastatic sites
(32, 37–39). In xenograft-bearing mice treated with trabecte-
din therapy, the reduced expression of CCL2 and CXCL8 was
paralleled by a marked decrease in the number of infiltrating
macrophages and vessels. In primary MLS cultures, IL-6 and
VEGF were also downmodulated by trabectedin. VEGF is a
key angiogenic factor, which certainly cooperates with the
florid vessel network of MLS. IL-6 is a growth-promoting
and antiapoptotic inflammatory cytokine (21, 40–43) and a
major effector signal of activated nuclear factor κB in the pro-
motion of neoplasia (44, 45).
In a previous collaborative study, we reported that PTX3
was one of the most expressed genes in MLS (46). We found
that trabectedin caused a marked downmodulation of PTX3
mRNA and protein. PTX3 belongs to the family of acute phase
proteins (which also includes CRP and SAP) and plays an im-
portant role in innate resistance to pathogens (30). In addi-
tion, PTX3 has been shown to be essential for the
construction of the ECM by forming complexes with the
TNF-regulated protein TSG6 which, in turn, combines with
hyaluronan (47). In the tumor microenvironment, the consti-
tution of a dynamic stroma is of overriding importance for the
enlarging tumor mass. Our data also show that trabectedin
affects the transcription and production of PTX3 only in the
presence of the FUS-CHOP transcript. No inhibition was ob-
served in a FUS/CHOP-negative liposarcoma cell line, nor in
monocytes and endothelial cells. Forni and colleagues recent-
ly observed by chromatin immunoprecipitation experimentswww.aacrjournals.org
on June 3, 202cancerres.aacrjournals.org Downloaded from that the FUS-CHOP transcript is bound to the PTX3 promoter
in the 402.91 cell line, providing a possible mechanistic expla-
nation for this selectivity (18). Immature adipocytes produce
PTX3 in response to TNF and IL-1, and PTX3 mRNA is re-
duced during terminal differentiation by long-chain fatty
acids (48). Thus, PTX3 is transiently expressed during normal
adipocyte differentiation (48) and the high levels in MLS may
reflect a “frozen” undifferentiated state.
Whether a decrease in PTX3 levels is relevant for the anti-
tumor activity of trabectedin in MLS is unknown. We at-
tempted to study in vitro the effect of PTX3 on MLS cell
lines 402.91 and 1765. PTX3 inhibition with blocking antibo-
dies, or its silencing in 402.91 cells with short interfering RNA
did not significantly impair tumor proliferation, nor suscep-
tibility to trabectedin (data not shown). More in general, the
role of PTX3 in cancer in unclear and its involvement, partic-
ularly in MLS biology, deserves further investigation. Of note,
MLS cell lines also expressed high levels of SPARC, another
matricellular protein that has been investigated in several tu-
mor types (49, 50). Unlike PTX3, SPARC was not modulated
by treatment with trabectedin.
In conclusion, we have examined the possible mechan-
isms of action of trabectedin in human MLS. Beyond a di-
rect and strong growth-inhibitory effect on cancer cells, this
drug significantly hampered the production of selected
proinflammatory cytokines such as IL-6, CCL2, CXCL8,
VEGF, and PTX3. The inhibition of some mediators was
confirmed in vivo in animals bearing MLS xenografts, paral-
leled by a marked decrease of infiltrating macrophages and
tumor vessels. Downregulation of key inflammatory mole-
cules in the tumor microenvironment might be of benefit
in light of the increasingly clear relationship between per-
sistent inflammation and cancer progression.
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